HSD17B13 and metabolic dysfunction-associated steatohepatitis: A GWAS study using a total of 37,173 patients identified a highly significant association between a splice variant (rs72613567:TA) in HSD17B13 with reduced levels of ALT and AST, and a reduced risk for NASH [43].